Cargando…

Dimethyl fumarate alters B‐cell memory and cytokine production in MS patients

We evaluated the effect of dimethyl fumarate (DMF) treatment on B‐cell memory and cytokine production in 18 patients with relapsing remitting multiple sclerosis (RRMS) using peripheral blood mononuclear cells obtained prior to and at 6 months post‐DMF initiation. We noted a decline in the absolute B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Matthew D., Martin, Kyle A., Calabresi, Peter A., Bhargava, Pavan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420807/ https://www.ncbi.nlm.nih.gov/pubmed/28491903 http://dx.doi.org/10.1002/acn3.411

Ejemplares similares

Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes
por: Bhargava, Pavan, et al.
Publicado: (2018)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
por: Kihara, Yasuyuki, et al.
Publicado: (2015)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
por: Gafson, Arie R., et al.
Publicado: (2018)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells
por: Staun-Ram, Elsebeth, et al.
Publicado: (2018)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
por: Timpani, Cara A., et al.
Publicado: (2020)

Dimethyl Fumarate Used as an Effective Treatment for Granuloma Annulare Disseminatum: An Immunohistochemical Case Study
por: Gabutti, Max, et al.
Publicado: (2023)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Alteration of Cytokine Production during Visceral Larva Migrans by Toxascaris leonina in Mice
por: Kang, Shin Ae, et al.
Publicado: (2013)

Dimethyl Fumarate Attenuates Lymphocyte Infiltration and Reduces Infarct Size in Experimental Stroke
por: Schuhmann, Michael K., et al.
Publicado: (2023)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure
por: Sorrenti, Valeria, et al.
Publicado: (2020)

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
por: Goldman, Myla D., et al.
Publicado: (2020)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Drug-Repurposing Strategy for Dimethyl Fumarate
por: Giunta, Salvatore, et al.
Publicado: (2023)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

BAFF blockade in experimental autoimmune encephalomyelitis reduces inflammation in the meninges and synaptic and neuronal loss in adjacent brain regions
por: Gupta, Kanak, et al.
Publicado: (2023)

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
por: Al-Omair, Abdullah, et al.
Publicado: (2022)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
por: Manai, Federico, et al.
Publicado: (2022)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study
por: Vucic, Steve, et al.
Publicado: (2021)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_20g36dus0q6s833p22erf59hdk